Metagenomi, Inc. Common Stock (MGX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.13 (+0.00%), Market cap $0.05B, 52-week low–high $1.26 ~ $3.35.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therap
Financial statements, price targets, institutional (13F) holdings and related news for Metagenomi, Inc. Common Stock are updated in real time on BlackAll Trade.
Metagenomi, Inc. Common Stock trades at $1.13 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Metagenomi, Inc. Common Stock has a market cap of about $0.05B.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curat